|Brand name(s), other common name(s)||Tibsovo®|
|Drug type||Isocitrate dehydrogenase-1 (IDH1) inhibitor|
|How the drug is given||By mouth|
Indications and Usage
Ivosidenib is FDA approved for the treatment of adult patients with relapsed or refractory acute myeloid leukemia (AML) with a susceptible IDH1 mutation as detected by an FDA-approved test..
Side effects needing medical attention
Fatigue, increased number of leukocytes (white blood cells) (leukocytosis), joint pain, diarrhea, difficulty breathing, excess of fluid in cavities or tissues of the body (edema), nausea, painful inflammation and ulceration of the mucous membranes lining the digestive tract (mucositis), electrocardiogram QT prolonged, rash, fever, cough, and constipation.